|
LOC110806263
|
Carcinogenesis
|
0.100 |
GeneticVariation |
BEFREE |
The tumors were sequenced for mutations in the TERT promoter and 22 additional cancer-related genes, interestingly; one patient was shown to carry a deleterious intronic variant in PTEN, a tumor suppressor gene coupled to thyroid tumorigenesis and Cowden syndrome.
|
31699114 |
2019 |
|
LOC110806263
|
Carcinogenesis
|
0.100 |
GeneticVariation |
BEFREE |
The majority of such HCC cases contain integrated HBV, and some hotspot integrations, such as those in the telomerase reverse transcriptase gene (TERT) promoter, activate gene expression to drive carcinogenesis.
|
30070724 |
2019 |
|
LOC110806263
|
Carcinogenesis
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutations (13.1% of R/M cases) were mutually exclusive with both NOTCH1 mutations (q = 3.3 × 10-4) and MYB/MYBL1 fusions (q = 5.6 × 10-3), suggesting discrete, alternative mechanisms of tumorigenesis.
|
31483290 |
2019 |
|
LOC110806263
|
Carcinogenesis
|
0.100 |
GeneticVariation |
BEFREE |
The acquisition of pathogenic variants in the TERT promoter (TERTp) region is a mechanism of tumorigenesis.
|
30523342 |
2019 |
|
LOC110806263
|
Carcinogenesis
|
0.100 |
GeneticVariation |
BEFREE |
Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis.
|
29599449 |
2018 |
|
LOC110806263
|
Carcinogenesis
|
0.100 |
GeneticVariation |
BEFREE |
Somatic telomerase reverse transcriptase (TERT) promoter mutations have been recently identified in several types of malignant tumors, including thyroid neoplasia; however, the actual role of TERT mutations in thyroid tumorigenesis is still under debate.
|
29435002 |
2018 |
|
LOC110806263
|
Carcinogenesis
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutations (73%) and chromatin-modifying gene alterations (69%) were highly prevalent across grade and stage, suggesting these events occur early in tumorigenesis.
|
28583311 |
2017 |
|
LOC110806263
|
Carcinogenesis
|
0.100 |
Biomarker |
BEFREE |
These results support a major role for telomere elongation in HCV-related and non-viral related hepatic carcinogenesis and suggest that TERT promoter mutations could represent a candidate biomarker for the early detection of liver cancer in subjects with HCV infection or with metabolic liver diseases.
|
28529542 |
2017 |
|
LOC110806263
|
Carcinogenesis
|
0.100 |
PosttranslationalModification |
BEFREE |
Induction of telomerase reverse transcriptase (TERT) expression coupled with telomerase activation is essential for cancer development/progression, while aberrant TERT promoter methylation has been linked to TERT induction in oncogenesis.
|
28754720 |
2017 |
|
LOC110806263
|
Carcinogenesis
|
0.100 |
PosttranslationalModification |
BEFREE |
Telomerase reverse transcriptase (TERT) expression is a hallmark in tumorigenesis and upregulated due to mutations and methylation of the human (h)TERT promoter.
|
26390879 |
2016 |
|
LOC110806263
|
Carcinogenesis
|
0.100 |
GeneticVariation |
BEFREE |
Although TERT promoter mutations seem to play significant roles in the pathogenesis of TC, the mechanisms by which they contribute to carcinogenesis remain elusive and future work is needed to fully assess the roles, interactions, and impact of these mutations on the pathogenesis, diagnosis, prognosis, and therapeutics of TC.
|
26902827 |
2016 |
|
LOC110806263
|
Carcinogenesis
|
0.100 |
GeneticVariation |
BEFREE |
This review highlights the fundamental and widespread role of TERT promoter mutations in tumorigenesis, including recent progress on their mechanism of transcriptional activation.
|
26941407 |
2016 |
|
LOC110806263
|
Carcinogenesis
|
0.100 |
GeneticVariation |
BEFREE |
The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer.
|
26143634 |
2015 |
|
LOC110806263
|
Carcinogenesis
|
0.100 |
GeneticVariation |
BEFREE |
In addition, lack of TERT promoter mutations in primary adenocarcinoma of bladder suggests that this entity may have different origin or carcinogenesis from those of UC.
|
26239299 |
2015 |
|
LOC110806263
|
Carcinogenesis
|
0.100 |
Biomarker |
BEFREE |
TERT promoter is one of most frequent mutational targets in liver cancer, and hepatocellular carcinogenesis is highly associated with the loss of telomere-dependent cellular senescence control.
|
25574106 |
2015 |
|
LOC110806263
|
Carcinogenesis
|
0.100 |
GeneticVariation |
BEFREE |
In order to improve the understanding of the role of TERT promoter mutation in liver tumorigenesis, the mutational status of the TERT promoter was analyzed in 78 hepatocellular carcinomas, 15 hepatocellular adenomas, and 52 intrahepatic cholangiocarciomas.
|
25267585 |
2014 |
|
LOC110806263
|
Carcinogenesis
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutation does not appear to be an early event during oncogenesis, as it was not detected in the contiguous endometriosis associated with ovarian clear cell carcinoma.
|
24338723 |
2014 |